Celecoxib

Generic Name: Celecoxib

Brand Names: Celebrex, Elyxyb, Seglentis

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₄F_₃N_₃O_₂S

CAS Number: 169590-42-5

Unique Ingredient Identifier: JCX84Q7J1L

Background: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...

Indication: Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...

Associated Conditions: Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain

Associated Therapies: -

Clinical Trials

Stony Brook Medicine Anti-Inflammatory Trial

Phase 4

Not yet recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: Celecoxib
Drug: Minocycline

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Stony Brook University

Target Recruit Count: 42

Registration Number: NCT06699966

Celecoxib for ENT Pain Management

Phase 2

Recruiting

Conditions: Parotidectomy

Interventions: Drug: Celecoxib
Drug: Tylenol
Drug: Oxycodone
Drug: placebo

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-05

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 84

Registration Number: NCT06505187

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries

Phase 4

Recruiting

Conditions: Postoperative Pain, Acute
Pain, Postoperative

Interventions: Drug: Acetaminophen
Drug: Celecoxib
Drug: Gabapentin

First Posted Date: 2024-04-23

Last Posted Date: 2024-04-23

Lead Sponsor: Northwell Health

Target Recruit Count: 70

Registration Number: NCT06379425

Locations: 🇺🇸
Northwell Health South Shore Surgery Center, Bay Shore, New York, United States

Impact of Opioid Avoidance Protocol for ACL Reconstruction

Recruiting

Conditions: ACL Tear
Post Operative Pain

Interventions: Device: Iovera
Drug: Celecoxib
Drug: Tramadol
Drug: Acetaminophen
Drug: Bupivacaine Hydrochloride
Drug: Acetaminophen 500Mg Cap
Drug: Oxycodone

First Posted Date: 2024-04-02

Last Posted Date: 2024-07-24

Lead Sponsor: Matthew Varacallo

Target Recruit Count: 40

Registration Number: NCT06340932

Locations: 🇺🇸
Penn Highlands Dubois, DuBois, Pennsylvania, United States

Evaluation of Clinical Efficacy of Herbal Compound in the Treatment of NSLBP

Phase 4

Completed

Conditions: Low Back Pain

Interventions: Drug: herbal compound
Drug: Celecoxib

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Zhejiang Provincial Tongde Hospital

Target Recruit Count: 71

Registration Number: NCT06336993

Locations: 🇨🇳
Tongde Hospital, Hangzhou, Zhejiang, China

Efficacy and Mechanism of FSN Treatment for Senile Knee Osteoarthritis

Not Applicable

Not yet recruiting

Conditions: Osteoarthritis, Knee

Interventions: Device: Fu's Subcutaneous Needling
Drug: Celecoxib

First Posted Date: 2024-03-25

Last Posted Date: 2024-03-25

Lead Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine

Target Recruit Count: 60

Registration Number: NCT06328153

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

Phase 4

Recruiting

Conditions: Knee Osteoarthritis

Interventions: Drug: Placebo
Drug: Duloxetine
Drug: Celecoxib

First Posted Date: 2024-02-07

Last Posted Date: 2024-07-24

Lead Sponsor: Northwestern University

Target Recruit Count: 180

Registration Number: NCT06245109

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

The Seven Trial: Exploiting the Unfolded Protein Response

Phase 1

Not yet recruiting

Conditions: Pancreatic Cancer Metastatic
Pancreatic Adenocarcinoma Metastatic

Interventions: Drug: Botensilimab
Drug: Balstilimab
Drug: Chloroquine Phosphate
Drug: Celecoxib

First Posted Date: 2023-10-11

Last Posted Date: 2023-10-11

Lead Sponsor: HonorHealth Research Institute

Target Recruit Count: 12

Registration Number: NCT06076837

Locations: 🇺🇸
Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Phase 1

Completed

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions: Drug: CCX168
Drug: Midazolam
Drug: Rifampicin
Drug: Celecoxib
Drug: Itraconazole

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Amgen

Target Recruit Count: 32

Registration Number: NCT06004947

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Pain Treatment With Combinations of NSAIDs

Not Applicable

Completed

Conditions: Postoperative Pain, Acute

Interventions: Drug: Celecoxib
Drug: Aspirin
Drug: Ketorolac

First Posted Date: 2023-08-16

Last Posted Date: 2024-01-25

Lead Sponsor: Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty

Target Recruit Count: 105

Registration Number: NCT05994287

Locations: 🇷🇺
Federal Center for Traumatology, Orthopedics and Endoprosthetics, Cheboksary, Chuvashia, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy